Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rad-IO: durvalumab with 5-fluorouracil/mitomycin C chemoradiotherapy in muscle-invasive bladder cancer
2018-003520-37Phase 2Unknown
- Sponsor
- University of Birmingham
- Start
- Aug 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of durvalumab in muscle-invasive bladder cancer (MIBC) and bladder cancer (2 arms), sponsored by University of Birmingham. Primary endpoint: Stage 1 primary endpoint. Status: unknown.
02
Drugs
durvalumab
03
Conditions
muscle-invasive bladder cancer (MIBC)bladder cancer
Beyond the preview
Go deeper on 2018-003520-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003520-37.